EN
登录

疫苗配方平台开发商VitriVax筹集1725万美元B轮融资,以推进疫苗配方平台的发展

VitriVax Raises $17.25 Million Series B Financing to Advance Vaccine Formulation Platform

vcaonline 等信源发布 2025-10-23 00:05

可切换为仅中文


VitriVax Raises $17.25 Million Series B Financing to Advance Vaccine Formulation Platform

VitriVax 获得 1725 万美元 B 轮融资,用于推进疫苗配方平台的发展

--Round led by Adjuvant Capital and RA Capital will enable scale-up of key clinical and regulatory operations--

--由Adjuvant Capital和RA Capital领投的本轮资金将助力关键临床和监管运营的扩展--

BOULDER, Colo., October 22, 2025-- VitriVax, Inc., a vaccine formulation technology company, today announced it raised a total of $17.25 million in Series B financing. The round was co-led by Adjuvant Capital and RA Capital Management, LP. Proceeds from the financing will be used for the continued development and commercialization of VitriVax’s proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology..

科罗拉多州博尔德,2025年10月22日——疫苗制剂技术公司VitriVax, Inc.今天宣布已完成1725万美元的B轮融资。本轮融资由Adjuvant Capital和RA Capital Management, LP共同领投。融资所得将用于继续开发和商业化VitriVax专有的原子层恒温抗原与佐剂(ALTA®)技术。

'The completion of our Series B financing marks an important milestone for VitriVax as we continue to advance the development of ALTA®, our thermostable, single-shot vaccine platform,' said Romulo Colindres, Chief Executive Officer of VitriVax. 'This funding positions us well to execute on our regulatory and clinical strategies, bringing us closer to addressing critical needs in vaccine access and immunization coverage.'.

“我们完成B轮融资对VitriVax而言是一个重要的里程碑,因为我们继续推进我们的耐热单剂疫苗平台ALTA®的开发,”VitriVax首席执行官Romulo Colindres表示。“这笔资金为我们执行监管和临床策略奠定了良好的基础,使我们更接近于满足疫苗获取和免疫覆盖的关键需求。”

Vaccines have transformed global health, yet significant challenges remain in ensuring equitable access and effective immunization. Many vaccines require strict cold-chain storage, making distribution to remote or resource-limited regions difficult and costly. Additionally, vaccines may require multiple doses which can pose logistical hurdles and increase healthcare burdens.

疫苗已经改变了全球健康状况,但在确保公平获取和有效免疫方面仍存在重大挑战。许多疫苗需要严格的冷链储存,这使得向偏远或资源有限的地区分发变得困难且成本高昂。此外,疫苗可能需要多次接种,这可能会带来物流障碍并增加医疗负担。

Designed to eliminate the need for cold-chain dependencies and enable a single-shot formulation for vaccines with dosing schedules, VitriVax’s ALTA® platform has the potential to increase access to lifesaving immunizations worldwide by simplifying distribution and vaccination schedules..

VitriVax的ALTA®平台旨在消除对冷链依赖的需求,并实现具有剂量计划的单剂疫苗配方,通过简化分发和接种计划,有潜力提高全球获得拯救生命的免疫接种的机会。

'We are pleased to support VitriVax as they work to address critical challenges in vaccine development and delivery,' said Glenn Rockman, Founder and Managing Partner at Adjuvant Capital. 'Thermostable, single-administration products have the potential to shift the paradigm in how vaccines are distributed and administered, potentially accelerating many long-sought public health goals.'.

“我们很高兴支持VitriVax,因为他们致力于解决疫苗研发和交付中的关键挑战,”Adjuvant Capital的创始人兼管理合伙人Glenn Rockman表示。“具有热稳定性和单次施用的产品有可能改变疫苗分发和接种的方式,可能加速许多长期以来追求的公共卫生目标。”

The Series B capital raise follows a $9.9 million grant from the Gates Foundation, which will support aseptic manufacturing of VitriVax’s ALTA® technology. The grant will enable Phase 1-ready GMP manufacturing and advance the platform to prepare for first-in-human clinical trials. In addition to grant funding from the Gates Foundation, VitriVax has also received a grant from the Coalition for Epidemic Preparedness Initiatives (CEPI), along with a significant multi-year contract from the Department of Defense..

B轮融资之前,维特里瓦克斯(VitriVax)公司获得了盖茨基金会990万美元的资助,这笔资金将用于支持其ALTA®技术的无菌生产。该资助将实现符合GMP标准的Phase 1生产,并推动该平台为首次人体临床试验做好准备。除了盖茨基金会的资助外,维特里瓦克斯还获得了流行病防范创新联盟(CEPI)的资助,以及来自国防部的一项重要多年合同。

About VitriVax

关于VitriVax

VitriVax, headquartered in Boulder, Colorado, is a vaccine formulation technology company that engineers innovative solutions to maximize global accessibility and utility of human vaccines – vaccines that save lives and protect our world from preventable disease.

VitriVax总部位于科罗拉多州博尔德,是一家疫苗制剂技术公司,致力于设计创新解决方案,以最大化人类疫苗的全球可及性和实用性——这些疫苗拯救生命并保护我们的世界免受可预防疾病的侵害。

Contact:

联系:

Julia Fuller

朱莉娅·富勒

Julia@Fullercomms.com

朱莉娅@富勒通讯.com

858-692-2001

858-692-2001